Literature DB >> 24126903

Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.

Almut G Winterstein1, Caitlin A Knox, Paul Kubilis, Christian Hampp.   

Abstract

IMPORTANCE Recommendations concerning the appropriate age threshold for respiratory syncytial virus (RSV) prophylaxis in moderate-preterm infants are highly debated. OBJECTIVE To determine the age at which moderate-preterm infants' risk of RSV hospitalization has decreased to the risk observed in low-risk term infants. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of Florida and Texas Medicaid fee-for-service billing records matched to birth certificates from Medicaid beneficiaries aged 0 to 12 months with a sibling younger than 5 years and without other indications for RSV prophylaxis between January 1, 1999, and December 31, 2004. EXPOSURES For each state, we used discrete time survival analysis to develop age trend models for RSV hospitalizations for 2 groups: moderate-preterm infants (32-34 weeks' gestational age) and term infants (37-41 weeks' gestational age). MAIN OUTCOMES AND MEASURES Age at which preterm infants' risk of RSV hospitalization equaled the risk for term infants at age 1 month. RESULTS Our cohort included 247,566 eligible infants with 5322 RSV hospitalizations. Preterm status doubled the risk for RSV hospitalization in both Florida (odds ratio = 2.41; 95% CI, 1.85-3.12) and Texas (odds ratio = 1.94; 95% CI, 1.64-2.30). Preterm infants' risk of RSV hospitalization was similar to that for 1-month-old term infants at ages 4.2 months (95% CI, 2.5-5.7) in Florida and 4.5 months (95% CI, 2.8-6.4) in Texas. CONCLUSIONS AND RELEVANCE The age at which moderate-preterm infants showed RSV hospitalization risk similar to their healthy term counterparts supports the more restrictive age thresholds in RSV immunoprophylaxis recommendations. Further studies are warranted to investigate the age-dependent risk of RSV hospitalization in other RSV risk groups.

Entities:  

Mesh:

Year:  2013        PMID: 24126903     DOI: 10.1001/jamapediatrics.2013.2636

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN: 2168-6203            Impact factor:   16.193


  21 in total

1.  Respiratory syncytial virus and palivizumab: Where are we in 2014?

Authors:  Joan Robinson
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

2.  Letters to the Editor.

Authors:  Karen Chang; Dennis Gurwitz; Peter Azzopardi; Shaheen Doctor; Ronik Kanani; Constantine Petrou; Paul Meinert; Meera Umamaheswaran Kissoon
Journal:  Paediatr Child Health       Date:  2016 Jun-Jul       Impact factor: 2.253

3.  Palivizumab Prophylaxis for Healthy Preterm Infants: More Data Supporting American Academy of Pediatrics Guidelines.

Authors:  Carrie L Byington; Flor M Munoz
Journal:  Pediatrics       Date:  2016-07-18       Impact factor: 7.124

4.  Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.

Authors:  Almut G Winterstein; Yoonyoung Choi; H Cody Meissner
Journal:  JAMA Pediatr       Date:  2018-02-01       Impact factor: 16.193

5.  Respiratory syncytial virus-associated mortality in hospitalized infants and young children.

Authors:  Carrie L Byington; Jacob Wilkes; Kent Korgenski; Xiaoming Sheng
Journal:  Pediatrics       Date:  2014-12-08       Impact factor: 7.124

6.  Breastfeeding progression in preterm infants is influenced by factors in infants, mothers and clinical practice: the results of a national cohort study with high breastfeeding initiation rates.

Authors:  Ragnhild Maastrup; Bo Moelholm Hansen; Hanne Kronborg; Susanne Norby Bojesen; Karin Hallum; Annemi Frandsen; Anne Kyhnaeb; Inge Svarer; Inger Hallström
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

7.  Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Authors:  Christopher S Ambrose; Evan J Anderson; Eric A F Simões; Xionghua Wu; Hanaa Elhefni; C Lucy Park; Frangiscos Sifakis; Jessie R Groothuis
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

8.  Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.

Authors:  John P DeVincenzo; Christopher S Ambrose; Doris Makari; Leonard B Weiner
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

Review 9.  Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.

Authors:  Josephine Mauskopf; Andrea V Margulis; Miny Samuel; Kathleen N Lohr
Journal:  Pediatr Infect Dis J       Date:  2016-07       Impact factor: 2.129

Review 10.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease.

Authors:  Josep Figueras-Aloy; Paolo Manzoni; Bosco Paes; Eric A F Simões; Louis Bont; Paul A Checchia; Brigitte Fauroux; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2016-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.